Share This Author
Local recurrences in giant cell tumour of bone
It was found that grading had no prognostic value in determining the prognosis of giant cell tumour (osteoclastoma) and the rate of local and distant recurrences in a consecutive series of 31 patients.
A Retrospective Clinicopathological Study of 37 Patients With Chordoma: A Danish National Series
It is concluded that effective treatment against chordomas is still lacking and a prospective multi-institutional registration study may provide more information on the optimal work-up and treatment of this rare disease.
Clinical and Histopathological Prognostic Factors in Chondrosarcomas
Although the grading of chondrosarcomas is in need of improvement, its replacement by semiquantitative evaluation of individual histopathological parameters as performed in this study offers no advantage.
Radiation treatment of giant-cell tumour of bone (osteoclastoma).
Ten patients with giant cell tumours of the bone treated by radiation therapy had 3 recurrences after radiation therapy, all occurring in patients with tumor doses less than 39 Gy; 2 of these had received orthovoltage therapy and 2 died later from lung metastases.
[Degenerative lumbar spondylolisthesis and spinal stenosis].
[Sarcoma treatment in Denmark].
In cases of osteogenic sarcoma, the data available at present suggest that prolongation of the survival rate may be obtained by means of intensive adjuvant cytostatic treatment, but the optimal regimen is not yet defined.
[Outbreak of methicillin resistant Staphylococcus aureus in a central hospital].
Bacteriophage-typing and DNA typing using pulsed field gel electrophoresis revealed that three different strains of MRSA were involved in the outbreak, emphasizing the importance of typing MRSA in order to clear up the spread in an outbreak.
Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
It is recommended that further trials with TGT await the development of more water-soluble formulations or of other triepoxide derivatives, as severe dose-limiting toxicity took the form of phlebitis becoming apparent a few days after treatment.
[Hepatitis C antibody in hematological patients who underwent multiple transfusions].
The clinical significance of the seropositivity is underlined by the finding at autopsy of chronic active hepatitis in one of the two patients found anti-HCV positive.